Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cetirizine
Therapeutic Area: Ophthalmology Product Name: Zerviate
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
Details:
The Phase 3 trial is evaluating the safety and efficacy of ZERVIATE , first and only topical ocular formulation of the antihistamine cetirizine, for the treatment of ocular itching associated with allergic conjunctivitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Conbercept
Therapeutic Area: Ophthalmology Product Name: Lumitin
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
Conbercept is a new generation anti-VEGF fusion protein, approved and marketed in China as Lumitin®, for the treatment of retina diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: OT-702
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Shandong Boan Biological Technology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 30, 2020
Details:
Ocumension has been granted the exclusive right to promote and commercialize OT-702 in China. OT-702 is in phase III clinical trial and is the company's third line product to enter phase III in China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NCX 470
Therapeutic Area: Ophthalmology Product Name: OT-301
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Nicox SA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Nicox and Ocumension will jointly fund the second NCX 470 Phase 3 glaucoma trial, Denali, which is expected to start by end of 2020 and will also evaluate NCX 470 ophthalmic solution, 0.1%, versus latanoprost ophthalmic solution, 0.005%.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bevacizumab
Therapeutic Area: Ophthalmology Product Name: HLX04
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Henlius
Deal Size: $25.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement October 15, 2020
Details:
Pursuant to the Agreement, Essex and Henlius will co-develop the bevacizumab HLX04 for treatment of ophthalmic diseases such as exudative (wet) Age-related Macular Degeneration (wAMD).
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
